42 Bibliografia [1] Snowden, J.A.; Sanchez-Ortega, I.; Corbacioglu, S.; Basak, G.W.; Chabannon, C.; de la Camara, R.; Dolstra, H.; Duarte, R.F.; Glass, B.; Greco, R.; et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant 2022, 57, 1217-1239, doi:10.1038/s41409-022-01691-w [2] Passweg, J.R.; Baldomero, H.; Chabannon, C.; Corbacioglu, S.; de la Camara, R.; Dolstra, H.; Glass, B.; Greco, R.; Mohty, M.; Neven, B.; et al. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplant 2022, 57, 742-752, doi:10.1038/s41409-022-01604-x [3] Algeri, M.; Merli, P.; Locatelli, F.; Pagliara, D. The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia. J Clin Med 2021, 10, doi:10.3390/jcm10173790 [4] Merli, P.; Algeri, M.; Del Bufalo, F.; Locatelli, F. Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep 2019, 14, 94-105, doi:10.1007/ s11899-019-00502-2 [5] Conter, V.; Bartram, C.R.; Valsecchi, M.G.; Schrauder, A.; Panzer-Grumayer, R.; Moricke, A.; Arico, M.; Zimmermann, M.; Mann, G.; De Rossi, G.; et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010, 115, 3206-3214, doi:10.1182/blood-2009-10-248146 [6] Schrappe, M.; Hunger, S.P.; Pui, C.H.; Saha, V.; Gaynon, P.S.; Baruchel, A.; Conter, V.; Otten, J.; Ohara, A.; Versluys, A.B.; et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 2012, 366, 1371-1381, doi:10.1056/NEJMoa1110169 [7] Pui, C.H.; Rebora, P.; Schrappe, M.; Attarbaschi, A.; Baruchel, A.; Basso, G.; Cave, H.; Elitzur, S.; Koh, K.; Liu, H.C.; et al. Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study. J Clin Oncol 2019, 37, 770779, doi:10.1200/JCO.18.00822 [8] Fischer, U.; Forster, M.; Rinaldi, A.; Risch, T.; Sungalee, S.; Warnatz, H.J.; Bornhauser, B.; Gombert, M.; Kratsch, C.; Stutz, A.M.; et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet 2015, 47, 1020-1029, doi:10.1038/ng.3362 [9] Mullighan, C.G.; Su, X.; Zhang, J.; Radtke, I.; Phillips, L.A.; Miller, C.B.; Ma, J.; Liu, W.; Cheng, C.; Schulman, B.A.; et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009, 360, 470-480, doi:10.1056/NEJMoa0808253 [10] Mann, G.; Attarbaschi, A.; Schrappe, M.; De Lorenzo, P.; Peters, C.; Hann, I.; De Rossi, G.; Felice, M.; Lausen, B.; Leblanc, T.; et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood 2010, 116, 2644-2650, doi:10.1182/blood-2010-03-273532 [11] Coustan-Smith, E.; Gajjar, A.; Hijiya, N.; Razzouk, B.I.; Ribeiro, R.C.; Rivera, G.K.; Rubnitz, J.E.; Sandlund, J.T.; Andreansky, M.; Hancock, M.L.; et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 2004, 18, 499-504, doi:10.1038/sj.leu.2403283 [12] Harrison, C.J.; Hills, R.K.; Moorman, A.V.; Grimwade, D.J.; Hann, I.; Webb, D.K.; Wheatley, K.; de Graaf, S.S.; van den Berg, E.; Burnett, A.K.; et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol 2010, 28, 2674-2681, doi:10.1200/ JCO.2009.24.8997 [13] Balgobind, B.V.; Raimondi, S.C.; Harbott, J.; Zimmermann, M.; Alonzo, T.A.; Auvrignon, A.; Beverloo, H.B.; Chang, M.; Creutzig, U.; Dworzak, M.N.; et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009, 114, 2489-2496, doi:10.1182/blood-2009-04-215152 [14] Pratcorona, M.; Brunet, S.; Nomdedeu, J.; Ribera, J.M.; Tormo, M.; Duarte, R.; Escoda, L.; Guardia, R.; Queipo de Llano, M.P.; Salamero, O.; et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood 2013, 121, 2734-2738, doi:10.1182/blood-2012-06-431122 [15] Buldini, B.; Rizzati, F.; Masetti, R.; Fagioli, F.; Menna, G.; Micalizzi, C.; Putti, M.C.; Rizzari, C.; Santoro, N.; Zecca, M.; et al. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. Br J Haematol 2017, 177, 116-126, doi:10.1111/bjh.14523 [16] de la Fuente, J.; Baruchel, A.; Biondi, A.; de Bont, E.; Dresse, M.F.; Suttorp, M.; Millot, F.; International, B.F.M.G.S.G.C.M.L.C. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol 2014, 167, 33-47, doi:10.1111/bjh.12977 [17] Locatelli, F.; Strahm, B. How I treat myelodysplastic syndromes of childhood. Blood 2018, 131, 1406-1414, doi:10.1182/blood-2017-09-765214 [18] Locatelli, F.; Algeri, M.; Merli, P.; Strocchio, L. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia. Expert Rev Hematol 2018, 11, 129-143, doi:10.1080/174 74086.2018.1421937 [19] Naik, S.; Martinez, C.A.; Omer, B.; Sasa, G.; Yassine, K.; Allen, C.E.; Kamdar, K.; Orth, R.; Wu, M.; Leung, K.; et al. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv 2019, 3, 2689-2695, doi:10.1182/bloodadvances.2018026203 [20] Lankester, A.C.; Neven, B.; Mahlaoui, N.; von Asmuth, E.G.J.; Courteille, V.; Alligon, M.; Albert, M.H.; Serra, I.B.; Bader, P.; Balashov, D.; et al. Hematopoietic cell transplantation in severe combined immunodeficiency: The SCETIDE 2006-2014 European cohort. J Allergy Clin Immunol 2022, 149, 1744-1754 e1748, doi:10.1016/j.jaci.2021.10.017 [21] Merli, P.; Pagliara, D.; Galaverna, F.; Li Pira, G.; Andreani, M.; Leone, G.; Amodio, D.; Pinto, R.M.; Bertaina, A.; Bertaina, V.; et al. TCRalphabeta/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders. Blood Adv 2022, 6, 281-292, doi:10.1182/bloodadvances.2021005628 [22] Bergsten, E.; Horne, A.; Hed Myrberg, I.; Arico, M.; Astigarraga, I.; Ishii, E.; Janka, G.; Ladisch, S.; Lehmberg, K.; McClain, K.L.; et al. Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study. Blood Adv 2020, 4, 3754-3766, doi:10.1182/bloodadvances.2020002101 [23] Albert, M.H.; Slatter, M.A.; Gennery, A.R.; Gungor, T.; Bakunina, K.; Markovitch, B.; Hazelaar, S.; Sirait, T.; Courteille, V.; Aiuti, A.; et al. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis. Blood 2022, 139, 2066-2079, doi:10.1182/blood.2021014687 [24] Magnani, A.; Semeraro, M.; Adam, F.; Booth, C.; Dupre, L.; Morris, E.C.; Gabrion, A.; Roudaut, C.; Borgel, D.; Toubert, A.; et al. Long-term safety and efficacy of lentiviral hematopoietic stem/ progenitor cell gene therapy for Wiskott-Aldrich syndrome. Nat Med 2022, 28, 71-80, doi:10.1038/s41591-021-01641-x [25] Chiesa, R.; Wang, J.; Blok, H.J.; Hazelaar, S.; Neven, B.; Moshous, D.; Schulz, A.; Hoenig, M.; Hauck, F.; Al Seraihy, A.; et al.
RkJQdWJsaXNoZXIy ODUzNzk5